Prostate Cancer Q&A With Key Opinion Leader David F. Penson, MD

Share this content:
David F. Penson, MD, MPH, answers Cancer Therapy Advisor’s questions on the most key recent developments in prostate cancer management.
David F. Penson, MD, MPH, answers Cancer Therapy Advisor’s questions on the most key recent developments in prostate cancer management.

David F. Penson, MD, MPH, is the Paul V. Hamilton, M.D. and Virginia E. Howd chair in Urologic Oncology and Professor of Urologic Surgery and Medicine at Vanderbilt University Medical Center at Vanderbilt University Medical Center in Nashville, TN.

He is director of the Center for Surgical Quality and Outcomes Research in the Vanderbilt Institute for Medicine and Public Health.

His primary research interest is in population-based cohorts and assessing patient-reported outcomes in conditions treated with surgical procedures, specifically prostate cancer.

Cancer Therapy Advisor asked Dr. Penson for his views about key recent developments in prostate cancer management.

If you had to pick the most important advance in prostate cancer management in the past 10 years, what would it be?

Dr. Penson: I think the most important advance we have seen in the past decade in prostate cancer management has been the discovery and approval of numerous agents that have been shown to prolong survival in castrate-resistant disease.

While none of these individual agents is “curative” on its own, all represent important steps in that direction. I can only imagine what will happen when we start combining therapies and adding other newly discovered agents.

A number of studies have demonstrated that multiparametric MRI can improve the accuracy of prostate cancer detection. Should clinicians use it routinely in the diagnostic work-up if it is available?

Dr. Penson: I completely agree that MRI has become an important adjunct to prostate biopsy that is improving our ability to detect prostate cancer. This is particularly true when the MRI is used in conjunction with ultrasound to perform a so-called fusion biopsy. I don't know if we should be using it routinely in all men at risk for prostate cancer, however.

This may not be the most cost-effective way to approach prostate cancer detection. In my practice, I try to reserve MRI-fusion TRUS [transrectal ultrasound] biopsy for men who have a rising PSA and a prior negative TRUS biopsy or men who I am following on active surveillance.

RELATED: ADT Not Linked With Greater Risk of Cardiac Death in Prostate Cancer Patients

I am particularly excited about MRI as it is applied to active surveillance, as it may ultimately allow us to avoid some repeat biopsies. That being said, we still need more research in this space.

It remains unclear whether robotic-assisted radical prostatectomy (RARP) results in better oncologic control, but evidence suggests this approach offers advantages over traditional surgery in terms of recovery of potency and urinary continence. Do these advantages by themselves justify the preferential use of RARP?

Dr. Penson: At this point, the question is effectively moot. Roughly 85% to 90% of prostatectomies performed in the United States use the robotic-assisted laparoscopic (RALP) approach, so from a purely quality of care perspective, RALP is preferred because it is the usual approach of most urologists in 2015.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs